BTAI / BioXcel Therapeutics' Igalmi Commercial Launch: Not As Bad As Some May Think

Trading penny stocks can be a risky endeavor, but having access to quality news and information can help mitigate some of that risk. As an investor or more_horizontal

Penny stocks are defined as stocks trading for under $5. They typically include start-up or emerging-growth stage companies starting from the grassroo more_horizontal

BioXcel Therapeutics (NASDAQ: BTAI ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced results from an audit of its more_horizontal

Shares of BioXcel Therapeutics Inc. BTAI, +0.86% jumped more than 40% premarket on Wednesday after the company said an independent audit of Alzheimer' more_horizontal

The company has one marketed treatment -- Igalmi, which reduces agitation in patients with bipolar disorder or schizophrenia. The most advanced candid more_horizontal

The biotech takes another hit following its earnings release on Monday. Several analysts became notably more bullish on its prospects. more_horizontal

Investors who've dipped their toe into the waters of biotech stocks know that the chances of these stocks crashing and burning is certainly higher tha more_horizontal

BioXcel announced Q2 results and a major strategic shift this morning. The biotech specialist has halted plans for Phase 2 clinical trials that were i more_horizontal